Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Disoproxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Disoproxil SCHEMBL16237284 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL985120 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL343783 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3234290 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL2670560 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL29356301 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL18190782 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3113154 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL1560984 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL497677 | 0.95 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13777 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026102058-A1 | METHODS FOR TREATING CHRONIC HEPATITIS B INFECTION AND RELATED FORMULATIONS | TUNE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4444311-B1 | GINSENOSIDES FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTIONS | MENDEL UNIV IN BRNO (CZ) | 2026-05-06 | — | — | EP | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| EP-4732002-A2 | MOLECULAR SIGNATURES OF LONG-TERM HEPATOCELLULAR CARCINOMA RISK IN NON-ALCOHOLIC FATTY LIVER DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| WO-2005000405-A2 | P38 KINASE INHIBITOR COMPOSITIONS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | claimed |
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | claimed |
| US-20040208921-A1 | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-10-21 | — | — | US | claimed |
| WO-2004064731-A2 | LIPID-DRUG FORMULATIONS AND METHODS FOR TARGETED DELIVERY OF LIPID-DRUG COMPLEXES TO LYMLPLHOID TISSUES | UNIVERSITY OF WASHINGTON (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004064846-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004064845-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| CN-1503669-A | Antiviral agents and methods of treating viral infections | ά�¶�ҩƷ��˾ | 2004-06-09 | — | — | CN | claimed |
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-12 | — | — | US | claimed |
| WO-2002085358-A2 | ANTIVIRAL AGENTS AND METHODS OF TREATING VIRAL INFECTIONS | VION PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | claimed |